- For Print
- June 17, 2009
Ʊ., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Ʊ”) announced today that the Company had established its new subsidiary, Ʊ GesmbH (Location: Vienna, General Manager: Georg Wager, “Ʊ Austria”) in Austria. Ʊ Austria is a subsidiary wholly-owned by Ʊ Europe Limited (Headquarters: Hatfield, UK, Chairman & CEO: Yutaka Tsuchiya, “Ʊ Europe”), the European subsidiary of Ʊ.
Ʊ entered into the Austrian market in 2005 setting up a branch of its German subsidiary Ʊ GmbH (Location: Frankfurt, Managing Director: Andreas Wiegand). The Austrian branch has been marketing Zonegran® and Inovelon® for the treatment of epilepsy, Neurobloc® for cervical dystonia, Prialt® for severe chronic pain, and also collaborating in the promotion of Aricept® for Alzheimer's Disease. It has also served as a support centre for marketing, medical and regulatory affairs for the business operations in Central and Eastern Europe.
With the establishment of a subsidiary in Austria, a subsidiary wholly-owned by Ʊ Europe, Ʊ will strengthen its business operations in Austria and Central and Eastern European countries in preparation for future possible business expansion in this region.
Ʊ currently has ten subsidiaries in Europe with the newly established Ʊ Austria. Ʊ will continue to strengthen its business operations in Europe and to address the diversified needs of patients and their families, thereby improving patient value.
[Ʊ Austria's Outline]
*You can scroll to the left or right here
Company Name : | Ʊ GesmbH |
Date of Establishment : | April 1, 2009 |
Capital : | 35 thousand euros |
Location : | Vienna, Austria |
General Manager : | Georg Wager |
Business Operations : | Sales and Promotion of Pharmaceutical Products |